AU2021356578A1 - Methods and compositions for the treatment and prevention of type 1 diabetes - Google Patents

Methods and compositions for the treatment and prevention of type 1 diabetes Download PDF

Info

Publication number
AU2021356578A1
AU2021356578A1 AU2021356578A AU2021356578A AU2021356578A1 AU 2021356578 A1 AU2021356578 A1 AU 2021356578A1 AU 2021356578 A AU2021356578 A AU 2021356578A AU 2021356578 A AU2021356578 A AU 2021356578A AU 2021356578 A1 AU2021356578 A1 AU 2021356578A1
Authority
AU
Australia
Prior art keywords
insulin
peptide
mammal
diabetes
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021356578A
Other languages
English (en)
Other versions
AU2021356578A9 (en
Inventor
Richard DI PAOLO
Mary S. MORRIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Mary Morris & Associates LLC
St Louis University
Original Assignee
Dr Mary Morris & Associates LLC
St Louis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Mary Morris & Associates LLC, St Louis University filed Critical Dr Mary Morris & Associates LLC
Publication of AU2021356578A1 publication Critical patent/AU2021356578A1/en
Publication of AU2021356578A9 publication Critical patent/AU2021356578A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021356578A 2020-10-08 2021-10-05 Methods and compositions for the treatment and prevention of type 1 diabetes Pending AU2021356578A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089122P 2020-10-08 2020-10-08
US63/089,122 2020-10-08
PCT/US2021/053537 WO2022076385A1 (en) 2020-10-08 2021-10-05 Methods and compositions for the treatment and prevention of type 1 diabetes

Publications (2)

Publication Number Publication Date
AU2021356578A1 true AU2021356578A1 (en) 2023-05-11
AU2021356578A9 AU2021356578A9 (en) 2023-07-13

Family

ID=81126224

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021356578A Pending AU2021356578A1 (en) 2020-10-08 2021-10-05 Methods and compositions for the treatment and prevention of type 1 diabetes

Country Status (7)

Country Link
US (1) US20240041986A1 (https=)
EP (1) EP4225352A4 (https=)
JP (1) JP2023544832A (https=)
CN (1) CN116847869A (https=)
AU (1) AU2021356578A1 (https=)
CA (1) CA3193994A1 (https=)
WO (1) WO2022076385A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1409640A (zh) * 1999-12-16 2003-04-09 伊莱利利公司 稳定性改善的多肽组合物
US7279457B2 (en) * 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20090023630A1 (en) * 2005-01-31 2009-01-22 Jan Wouter Drijfhout Methods and Means for Use in Diagnostics and Treatment of Diabetes
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
US10905727B2 (en) * 2016-01-14 2021-02-02 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
US20200087374A1 (en) * 2017-02-06 2020-03-19 Resiliun B.V. Interaction between c-peptides and elastin receptor, a model for understanding vascular disease
EP3589271A4 (en) * 2017-02-28 2021-01-06 Biolingus IP LLC OIL BASED FORMULATIONS FOR SUBLINGUAL AND BUCCAL ADMINISTRATION
CN110662551B (zh) * 2017-06-01 2023-07-18 伊莱利利公司 速效胰岛素组合物
EP3823644A4 (en) * 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes

Also Published As

Publication number Publication date
EP4225352A1 (en) 2023-08-16
WO2022076385A1 (en) 2022-04-14
JP2023544832A (ja) 2023-10-25
CN116847869A (zh) 2023-10-03
CA3193994A1 (en) 2022-04-14
AU2021356578A9 (en) 2023-07-13
EP4225352A4 (en) 2024-01-10
US20240041986A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
EP1928499B1 (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
Bhavsar et al. Evolution of exenatide as a diabetes therapeutic
EP1988100B1 (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
Kuerzel et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects
US7049284B2 (en) Glucagon-like peptide-2 and its therapeutic use
US8481490B2 (en) Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis
Thompson et al. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin
AU2005271526B2 (en) Antidiabetic oral insulin-biguanide combination
US20160136246A1 (en) Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes
US12551537B2 (en) Methods and compositions for the treatment and prevention of type 1 diabetes
US20240041986A1 (en) Methods and compositions for the treatment and prevention of type 1 diabetes
Wasilewska et al. Semaglutide-properties, action and chromatographic analysis
US20160002310A1 (en) Modified ingap peptides for treating diabetes
US10105334B2 (en) Particle formulations of all-trans retinoic acid and transforming growth factor beta for the treatment of type 1 diabetes mellitus
Christensen et al. Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes
HK40078570B (en) Methods and compositions for the prevention of type 1 diabetes
HK40078570A (en) Methods and compositions for the prevention of type 1 diabetes
US20050176637A1 (en) Peptides
Tatar The role of hepatitis C virus genotypes in development of autoimmune diseases
Ohneda Effect of Glicentin-Related Peptides on Endocrine Function of Pancreas in Dogs¹
Qin et al. A Novel Dual-Function GLP-1 Analogue Prevents Type 1 Diabetes Onset in NOD Mice by Controlling the Balance of Treg/Th17 and Th2/Th1
Ishizuka et al. Evaluation of insulin secretion and sensitivity in a patient with slowly progressive type 1 diabetes mellitus
Dhoha et al. A case of insulin antibody-mediated insulin resistance in type 2 diabetes treated by glucocorticoid
HK1125653A (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
HK1153482A (en) Glucagon-like peptide-2 derivatives and their therapeutic use

Legal Events

Date Code Title Description
SREP Specification republished